SCHEMBL6735875

SCHEMBL6735875

CCS(=O)(=O)N(Cc1ccccn1)c1ccc(Oc2ccccc2)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 5/20 0.46
MAPK14 Q16539 1/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.39
CYP11B2 P19099 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
LMNA P02545 3/20 0.37
HTT P42858 2/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
KDM4E B2RXH2 2/20 0.37
NR3C1 P04150 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6731207 0.89 GRM2 (0.41) GRM2MAPK14KMT2AALDH1A1MEN1
SCHEMBL6739470 0.83 GRM2 (0.63) GRM2MAPK14KMT2AMMP2MMP9
SCHEMBL6732793 0.83 GRM2 (0.65) GRM2KMT2AALDH1A1MEN1
SCHEMBL6727845 0.82 GRM2 (0.45) GRM2MAPK14KMT2AALDH1A1MEN1
SCHEMBL6731086 0.81 GRM2 (0.39) GRM2KMT2ACYP11B2NPC1RAB9A
SCHEMBL6733828 0.81 GRM2 (0.72) GRM2
SCHEMBL6736493 0.78 GRM2 (0.57) GRM2MAPK14KMT2AMMP2MMP9
SCHEMBL6734960 0.76 GRM2 (0.55) GRM2MAPK14KMT2AMMP2MMP9
SCHEMBL6727564 0.76 GRM2 (0.60) GRM2MMP2MMP9NR3C1
SCHEMBL6730834 0.76 GRM2 (0.54) GRM2KMT2AMEN1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800651-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-10-05 US claimed
US-20040006114-A1 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-01-08 US claimed
EP-1255735-A2 PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2002-11-13 EP claimed
WO-2001056990-A2 PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2001-08-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006114-A1 Potentiators of glutamate receptors GRM1, GRIN1, GRM2 GRM2 3/4885MAPK14 3282/4885KMT2A 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.